Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir in HCV Patients on Dialysis
NCT03036852Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2017
- Primary completion
- Aug 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Mar 2017; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03036852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036852.